In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson highlights the fact that despite the difference in progression-free survival between the early transplant and delayed transplant arms of the study, there was no overall impact on overall survival gain, which he believes to be a highly important finding.
Richardson also discussed data showing that African-American patients may have an option to keep
